January 6, 2017 — SyntheticMR AB introduced REMyDI for automatic quantification of myelin volume in the brain at the 2016 annual meeting of the Radiological Society of North America (RSNA) in November. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a feature of the SyMRI post-processing software from SyntheticMR.
Measuring myelin volume with conventional magnetic resonance imaging (MRI) is challenging. With the REMyDI feature in SyMRI, clinicians can now get an automatic volume measurement of myelin from a single 5-6 minute quantitative MRI scan. The automatic post-processing is completed in less than 10 seconds.
"The advantage of retrieving a myelin estimation from a quantitative MR sequence that can also provide relaxometry-based volumetry and multiple contrasts is that a large amount of information is collected using a single, six-minute long acquisition. At Karolinska we have used REMyDI in studies of MS-patients and patients with neurodegenerative diseases,” said Tobias Granberg, M.D., Ph.D., Karolinska University Hospital, Sweden."
The REMyDI feature is available in the SyMRI Research Edition package and will be available for clinical use in the SyMRI Neuro package in 2017.
SyMRI is compatible with MR scanners from leading vendors and was demonstrated in the booths of SyntheticMR’s partners at RSNA. SyMRI is a CE-marked product and is U.S. Food and Drug Administration (FDA) 510(k) pending.
For more information: www.syntheticmr.com
April 17, 2024 
